stockportfolio.pro
Dianthus Therapeutics, Inc. (DNTH)
Healthcare · Biotechnology · NasdaqCM
Dianthus Therapeutics, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $1.48M | $6.42M | $2.83M | $6.24M | $2.04M |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | $-9.43M | $-35.49M | $-57.52M | $-76.77M | $-74.94M | $-71.14M | $-28.48M | $-43.55M | $-84.97M | $-162.34M |
| Net margin | — | — | — | — | — | -4819.5% | -443.8% | -1541.2% | -1362.8% | -7973.3% |
Source: Dianthus Therapeutics, Inc. SEC filings (10-K).
Explore 10 years of Dianthus Therapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track DNTH in your portfolio →
Dianthus Therapeutics, Inc. financial history by metric
About Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Dianthus Therapeutics, Inc. — frequently asked questions
What is Dianthus Therapeutics, Inc.'s revenue?
Dianthus Therapeutics, Inc. (DNTH) reported revenue of $2.04M for fiscal year 2025, down 67.3% from the prior year, according to its SEC filings.
Is Dianthus Therapeutics, Inc. profitable?
No — DNTH reported a net loss of $-162.34M in fiscal 2025.
What is DNTH's P/E ratio?
Dianthus Therapeutics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Dianthus Therapeutics, Inc. have?
As of fiscal year 2025, DNTH carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Dianthus Therapeutics, Inc.'s market cap?
Dianthus Therapeutics, Inc. (DNTH) has a market capitalization of about $4.38B, based on the latest data in our nightly-refreshed cache.
When does Dianthus Therapeutics, Inc.'s fiscal year end?
DNTH's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Dianthus Therapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 10 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.